莱博雷生临床应用中国专家共识

摘要： 失眠是最常见的睡眠紊乱，显著影响患者的生活质量和工作表现，且与躯体疾病、精神障碍等疾病相关。莱博雷生作为新型催眠药，是中国首个获批上市的食欲素双受体拮抗剂（DORA）。然而，目前我国尚缺乏莱博雷生临床应用的相关规范。为此，中国睡眠研究会、广东省医师协会睡眠医学专业委员会和广东省医院协会医院药事管理专业委员会组织国内药学和临床医学领域专家，依据国内外研究进展，结合中国首个莱博雷生的真实世界研究，制订《莱博雷生临床应用中国专家共识》。本共识针对莱博雷生的药理作用、药代动力学、适应证、临床应用方法等进行阐述，经过多轮讨论、修订和投票表决后最终形成17条推荐意见，以期为莱博雷生的临床应用提供全面而规范的参考和建议。

关键词: 莱博雷生, 失眠, 食欲素双受体拮抗剂, 临床应用

Abstract:

Insomnia is the most common sleep disorder. It not only significantly disturbs patients' quality of life and occupational performance, but is also associated with physical illness and mental disorders. Lemborexant, a new type of hypnotic drug, is the first dual orexin receptor antagonist (DORA) approved in China. However, there's still a lack of standardized guidelines for the usage of Lemborexant in China. Therefore, Chinese Sleep Research Society, the Sleep Medicine Professional Committee of Guangdong Medical Doctor Association and the Pharmacy Administration Committee of Guangdong Province Hospital Association collaborated with domestic experts in pharmacology and clinical medicine to develop the Expert Consensus on the Clinical Application of Lemborexant in China, elaborating on the pharmacological effects, pharmacokinetics, indications, and clinical application methods of Lemborexant. After multiple rounds of discussions, revisions, and voting, 17 recommendations were finally reached, aiming to provide comprehensive and standardized references and suggestions for the clinical application of Lemborexant.

Key words: Lemborexant, Insomnia, Dual orexin receptor antagonist, Clinical application

引用本文

中国睡眠研究会,广东省医师协会睡眠医学专业委员会,广东省医院协会医院药事管理专业委员会,等. 莱博雷生临床应用中国专家共识[J]. 中国全科医学, 2026, 29(05): 545-558.